Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the initiation of two clinical trials for IPI-549, a first-in-class, oral...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Samuel Agresta, M.D., will transition from his role as Chief Medical Officer to...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2019 financial results and provided an update on the company,...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, July 30, 2019 at 8:00 a.m. ET to review its second quarter 2019 ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that members of the management team will be participating in the 2019 BIO International ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2019 financial results and provided an update on the company,...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 7, at 4:30 p.m. ET to review its first quarter 2019...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full year 2018 financial results and provided an update on the company, including...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement under which Roche will...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, March 14, 2019, at 8:00 a.m. ET to review its full year 2018...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today a royalty monetization with HealthCare Royalty Partners (HCR) for the right to receive...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced anticipated 2019 milestones for IPI-549, a first-in-class, oral, immuno-oncology...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019,...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that data to be presented today at the 33rd Annual Meeting of the Society for Immunotherapy...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its...
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that an abstract describing data from the expansion of the MARIO-1 Phase 1b Study of...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Monday, November 5, 2018, at 4:30 p.m. ET to review its third quarter...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the BIO Investor Forum on Wednesday, October 17, 2018, at 11:15 a.m. PT (2:15 p.m....
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it earned a $22 million payment from Verastem Oncology under the license agreement ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at Cantor Fitzgerald's Global Healthcare Conference on Tuesday, October 2, 2018, at...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.